Healthcare Professionals
Versa
Pacemaker
You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
Medtronic Canada does not review or control the content on the other website, and is not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
Healthcare Professionals
Pacemaker
The Versa® Pacing System combines physiologic pacing with automaticity. It’s versatile and automatic.
Reducing unnecessary ventricular pacing has been shown to improve clinical outcomes by reducing the risks of atrial fibrillation (AF)1-4 and heart failure hospitalization (HFH)1,4
There is a 1% increase in the risk of AF for each 1% increase in cumulative right ventricular pacing.4
Changes in a patient's disease and/or medications may alter the efficacy of a device's programmed parameters or related features.
Risk of AF
RV pacing > 40% of the time in DDDR mode was associated with a 2.6-fold increased risk of HFH compared with pacing < 40%.4
How the Versa Pacing System Works
The new standard of care in pacing is to reduce unnecessary right ventricular pacing to as close to zero as possible. Mounting evidence suggests that right ventricular pacing is associated with a variety of detrimental effects, including risk of heart failure hospitalization and atrial fibrillation.1 The Versa pacing system combines physiologic pacing with automaticity.
Risk of Heart Failure Hospitalization (HFH) 1
Atrial Capture Management and Ventricular Capture Management (ACM and VCM):
TherapyGuide simplifies programming
Detail - Quick Look II on One Screen
Concise information to:
* Atrial Arrhythmia Trend of patient who received a change in antiarrhythmic drug therapy during an August follow-up. The change in medical therapy resulted in the decreased incidence and duration of AT/AF.
Rate Histogram of ventricular beats during exercise-induced AT/AF showing blocked conduction.
Rate Histogram of ventricular beats showing good conduction and rate control following change to patient's pharmacologic therapies for AT/AF.
† The information collected may help with assessment of rate control and risk for stroke in patients with atrial tachyarrhythmias.
Pacing therapies that may help manage tachyarrhythmias and may alleviate symptoms:
Therapeutic options for atrial tachycardia and atrial fibrillation
Medtronic CareLink® Network, the leading Internet-based remote monitoring service, is now available for pacemakers.
* Median number
Sweeney M, Hellkamp A, Ellenbogen K, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937.
Melzer C, Sowelam S, Sheldon TJ, et al. Reduction of right ventricular pacing in patients with sinus node dysfunction using an enhanced search AV algorithm. Pacing Clin Electrophysiol. June 2005; 28(6):521-527.
Sperzel J, Milasinovic G, Smith TW, et al. Automatic measurement of atrial pacing thresholds in dual-chamber pacemakers: Clinical experience with atrial capture management. Heart Rhythm. 2005;2(11):1203-1210.
Specifications
Mechanical | ||||||
---|---|---|---|---|---|---|
Model | Size (HxWxD mm) | M (g) | V (cc) | Connector | Radiopaque ID | |
VEDRO1 | 44.7x44.9x7.5 | 27.1 | 12.1 | 1S-1 BI or UNI | PWB or PWH | |
Battery | ||||||
Type | Lithium-iodine | |||||
Voltage | 2.8V | |||||
Average Projected Capacity | 1.3 Ah | |||||
Longevity | with SAV+ off 8.9 years* |
with SAV+ on 9.4 years** |
* DDDR OR DDD, 60 ppm, 100% pacing, ventricular 2.0V," atrial 1.5V," 0.4 ms pulse width, 1000 Ω pacing impedance, pre-arrhythmia EGM storage ON for 8 weeks per year
** SAV+ ON 50% pacing
Anderson HR, Nielsen JC, Thomsen PEB, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997;350:1210-1216.
Skanes AC, Krahn AD, Yee R, et al, for the CTOPP Investigators. Progression to chronic atrial fibrillation after pacing: The Canadian Trial Of Physiologic Pacing. J Am Coll Cardiol. 2001;38:167-172.
Neilsen J, Kristensen L, Andersen H, et al. A randomized comparison of atrial and dual chamber pacing in 177 consecutive patients with sick sinus syndrome. J Am Col Cardiol. 2003;42:614-623.
Sweeney M, Hellkamp A, Ellenbogen K, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937.